154 related articles for article (PubMed ID: 35083924)
1. Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer.
Brown LC; Graham J; Fisher D; Adams R; Seligmann J; Seymour M; Kaplan R; Yates E; Parmar M; Richman SD; Quirke P; Butler R; Shiu K; Middleton G; Samuel L; Wilson RH; Maughan TS;
Clin Trials; 2022 Apr; 19(2):146-157. PubMed ID: 35083924
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial.
Adams R; Brown E; Brown L; Butler R; Falk S; Fisher D; Kaplan R; Quirke P; Richman S; Samuel L; Seligmann J; Seymour M; Shiu KK; Wasan H; Wilson R; Maughan T;
Lancet Gastroenterol Hepatol; 2018 Mar; 3(3):162-171. PubMed ID: 29254887
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of WEE1 Is Effective in
Seligmann JF; Fisher DJ; Brown LC; Adams RA; Graham J; Quirke P; Richman SD; Butler R; Domingo E; Blake A; Yates E; Braun M; Collinson F; Jones R; Brown E; de Winton E; Humphrey TC; Parmar M; Kaplan R; Wilson RH; Seymour M; Maughan TS;
J Clin Oncol; 2021 Nov; 39(33):3705-3715. PubMed ID: 34538072
[TBL] [Abstract][Full Text] [Related]
4. Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial.
Adams RA; Fisher DJ; Graham J; Seligmann JF; Seymour M; Kaplan R; Yates E; Parmar M; Richman SD; Quirke P; Butler R; Brown E; Collinson F; Falk S; Wasan H; Shiu KK; Middleton G; Samuel L; Wilson RH; Brown LC; Maughan TS;
J Clin Oncol; 2021 Nov; 39(33):3693-3704. PubMed ID: 34516759
[TBL] [Abstract][Full Text] [Related]
5. Changing platforms without stopping the train: experiences of data management and data management systems when adapting platform protocols by adding and closing comparisons.
Hague D; Townsend S; Masters L; Rauchenberger M; Van Looy N; Diaz-Montana C; Gannon M; James N; Maughan T; Parmar MKB; Brown L; Sydes MR;
Trials; 2019 May; 20(1):294. PubMed ID: 31138292
[TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
7. Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial.
Richman SD; Adams R; Quirke P; Butler R; Hemmings G; Chambers P; Roberts H; James MD; Wozniak S; Bathia R; Pugh C; Maughan T; Jasani B;
J Clin Pathol; 2016 Jan; 69(1):35-41. PubMed ID: 26350752
[TBL] [Abstract][Full Text] [Related]
8. MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG).
Siu HWD; Tebbutt N; Chantrill L; Karapetis C; Steer C; Wilson K; Espinoza D; Bailey L; Yip S; Cuff J; Pavlakis N; Thavaneswaran S; Briscoe K; Srivastav R; Shannon J; Segelov E; Tie J; Caird S; Francesconi A; Price T; Wuttke M; Ladwa R; Sjoquist K; Burge M
BMC Cancer; 2021 Aug; 21(1):932. PubMed ID: 34407800
[TBL] [Abstract][Full Text] [Related]
9. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
10. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
11. This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols.
Schiavone F; Bathia R; Letchemanan K; Masters L; Amos C; Bara A; Brown L; Gilson C; Pugh C; Atako N; Hudson F; Parmar M; Langley R; Kaplan RS; Parker C; Attard G; Clarke NW; Gillessen S; James ND; Maughan T; Sydes MR;
Trials; 2019 May; 20(1):264. PubMed ID: 31138317
[TBL] [Abstract][Full Text] [Related]
12. Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study.
Sastre J; García-Alfonso P; Viéitez JM; Cano MT; Rivera F; Reina-Zoilo JJ; Salud-Salvia A; Quintero G; Robles-Díaz L; Safont MJ; La Casta A; Gil S; Polo E; Asensio-Martínez E; García-Paredes B; López RL; Guillot M; Valladares-Ayerbes M; Aranda E; Díaz-Rubio E;
ESMO Open; 2021 Apr; 6(2):100062. PubMed ID: 33711671
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.
Chan DLH; Segelov E; Wong RS; Smith A; Herbertson RA; Li BT; Tebbutt N; Price T; Pavlakis N
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007047. PubMed ID: 28654140
[TBL] [Abstract][Full Text] [Related]
14. ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours.
Segelov E; Waring P; Desai J; Wilson K; Gebski V; Thavaneswaran S; Elez E; Underhill C; Pavlakis N; Chantrill L; Nott L; Jefford M; Khasraw M; Day F; Wasan H; Ciardiello F; Karapetis C; Joubert W; van Hazel G; Haydon A; Price T; Tejpar S; Tebbutt N; Shapiro J
BMC Cancer; 2016 May; 16():339. PubMed ID: 27246726
[TBL] [Abstract][Full Text] [Related]
15. FOCUS4 biomarker laboratories: from the benefits to the practical and logistical issues faced during 6 years of centralised testing.
Richman SD; Hemmings G; Roberts H; Gallop N; Dodds R; Wilkinson L; Davis J; White R; Yates E; Jasani B; Brown L; Maughan TS; Butler R; Quirke P; Adams R
J Clin Pathol; 2023 Aug; 76(8):548-554. PubMed ID: 35256486
[TBL] [Abstract][Full Text] [Related]
16. Evaluating many treatments and biomarkers in oncology: a new design.
Kaplan R; Maughan T; Crook A; Fisher D; Wilson R; Brown L; Parmar M
J Clin Oncol; 2013 Dec; 31(36):4562-8. PubMed ID: 24248692
[TBL] [Abstract][Full Text] [Related]
17. Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study.
André T; Falcone A; Shparyk Y; Moiseenko F; Polo-Marques E; Csöszi T; Campos-Bragagnoli A; Liposits G; Chmielowska E; Aubel P; Martín L; Fougeray R; Amellal N; Saunders MP
Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):133-144. PubMed ID: 36470291
[TBL] [Abstract][Full Text] [Related]
18. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K
BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936
[TBL] [Abstract][Full Text] [Related]
19. The FOCUS4 design for biomarker stratified trials.
Kaplan R
Chin Clin Oncol; 2015 Sep; 4(3):35. PubMed ID: 26408302
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
